RT @doctorRBC: 2nd Plenary Session! Remibrutinib (BTK inhibitor) for treatment of Sjögren's syndrome (phase 2 study) I
Tweet Content
2nd Plenary Session!
Remibrutinib (BTK inhibitor) for treatment of Sjögren's syndrome (phase 2 study)
Improvement of ESSDAI, salivary flow and pathologically elevated Ig's
Abs#1113 @RheumNow #ACR22 https://t.co/vdgxBPe6qd
Show on Archive Page
On
Display in Search Results
On
PDQ
Off